231 related articles for article (PubMed ID: 25887090)
1. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study.
Mollers M; King AJ; Knol MJ; Scherpenisse M; Meijer CJ; van der Klis FR; de Melker HE
Vaccine; 2015 May; 33(23):2678-83. PubMed ID: 25887090
[TBL] [Abstract][Full Text] [Related]
2. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands.
Mollers M; Boot Hein J; Vriend Henrike J; King Audrey J; van den Broek Ingrid VF; van Bergen Jan EA; Brink Antoinette AT; Wolffs Petra FG; Hoebe Christian JP; Meijer Chris JL; van der Sande Marianne AB; de Melker Hester E
Vaccine; 2013 Jan; 31(2):394-401. PubMed ID: 23146675
[TBL] [Abstract][Full Text] [Related]
4. Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females.
van der Weele P; Breeuwsma M; Donken R; van Logchem E; van Marm-Wattimena N; de Melker H; Meijer CJLM; King AJ
PLoS One; 2019; 14(3):e0212927. PubMed ID: 30830913
[TBL] [Abstract][Full Text] [Related]
5. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
7. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
9. Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.
Hoes J; King AJ; Klooster TMSV; Berkhof J; Bogaards JA; de Melker HE
J Infect Dis; 2022 Sep; 226(4):634-643. PubMed ID: 33964158
[TBL] [Abstract][Full Text] [Related]
10. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
11. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR;
J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910
[TBL] [Abstract][Full Text] [Related]
12. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
13. Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches.
Donken R; Hoes J; Knol MJ; Ogilvie GS; Dobson S; King AJ; Singer J; Woestenberg PJ; Bogaards JA; Meijer CJLM; de Melker HE
BMC Infect Dis; 2020 Jul; 20(1):482. PubMed ID: 32640998
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
15. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
[TBL] [Abstract][Full Text] [Related]
16. Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach.
Bogaards JA; Mooij SH; Xiridou M; Schim van der Loeff MF
PLoS Med; 2019 Mar; 16(3):e1002756. PubMed ID: 30830901
[TBL] [Abstract][Full Text] [Related]
17. Persisting Antibody Response 9 Years After Bivalent Human Papillomavirus (HPV) Vaccination in a Cohort of Dutch Women: Immune Response and the Relation to Genital HPV Infections.
Hoes J; Pasmans H; Knol MJ; Donken R; van Marm-Wattimena N; Schepp RM; King AJ; van der Klis FRM; de Melker HE
J Infect Dis; 2020 May; 221(11):1884-1894. PubMed ID: 31917429
[TBL] [Abstract][Full Text] [Related]
18. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
20. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
